TY - JOUR
T1 - Treatment response in pediatric patients with pseudotumor cerebri syndrome
AU - Tovia, Eliel
AU - Reif, Shimon
AU - Oren, Asaf
AU - Mitelpunkt, Alexis
AU - Fattal-Valevski, Aviva
N1 - Publisher Copyright:
Copyright © 2017 North American Neuro-Ophthalmology Society.
PY - 2017
Y1 - 2017
N2 - Background: Pseudotumor cerebri syndrome (PTCS) is a disorder defined by increased intracranial pressure in the absence of an intracranial space-occupying lesion. This retrospective study aimed to examine the outcomes in children with PTCS. Methods: Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males). Results: Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P < 0.05). Conclusions: Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.
AB - Background: Pseudotumor cerebri syndrome (PTCS) is a disorder defined by increased intracranial pressure in the absence of an intracranial space-occupying lesion. This retrospective study aimed to examine the outcomes in children with PTCS. Methods: Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males). Results: Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P < 0.05). Conclusions: Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.
UR - http://www.scopus.com/inward/record.url?scp=85039868911&partnerID=8YFLogxK
U2 - 10.1097/WNO.0000000000000516
DO - 10.1097/WNO.0000000000000516
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28787297
AN - SCOPUS:85039868911
SN - 1070-8022
VL - 37
SP - 393
EP - 397
JO - Journal of Neuro-Ophthalmology
JF - Journal of Neuro-Ophthalmology
IS - 4
ER -